This impact was particularly evident in combination with angiotensin-converting enzyme inhibitors (ACE-I) and decrease in eGFR ≤ 60 mL/min/1.73 m2 (p = 0.033) in the presence of OH, similarly to a combination of treatment with β-blockers with congestive heart failure (CHF) and eGFR ≤ 60 mL/min/1.73 m2 (p = 0.005), as well as other correlations. This evidence concerns the gene ACE and congestive heart failure.